Boston-based Dana-Farber Cancer Institute recorded an operating income of $91.5 million (8.4% operating margin) in the first quarter of 2026, up from $69.1 million (7% margin) during the same period last year, according to its March 11 financial report.
Dana-Farber recorded total operating revenue of $1.1 billion for the three months ended Dec. 31, up from $982.8 million during the same period last year. Net patient service revenue was $822.3 million, up from $727.9 million. Dana-Farber attributed the 13% year-over-year growth in net patient service revenue to an increase in patient volume and pharmacy revenue. Clinic visits grew 3.9% year over year and infusion visits increased 6.7%. Direct research revenue was $148.7 million, up from $137.1 million.
Total operating expenses were $1 billion in the first quarter of 2026, up from $910.5 million during the same period last year. Total patient service expenses were $670.2 million, up from $590 million. Total research expenses were $171.8 million, up from $158.6 million. Total general and administrative expenses were $158.6 million, down from $161.8 million, which the system attributed to a decrease in legal and consulting expenses.
Dana-Farber recorded a net income of $133 million in the first quarter of 2026, up from $108.4 million during the same period last year.
The post Dana-Farber boosts operating margin to 8.4% in Q1 appeared first on Becker's Hospital Review | Healthcare News & Analysis.
Source: Read Original Article
